Lerin 5 mg implantat
Name | Lerin 5 mg implantat |
---|---|
Former Name | Leuprone 5 mg implantat |
Marketing Authorisation Number | HR-H-468174689 |
Active Substance | leuprorelinacetat |
Composition | 1 implantat sadrži 5 mg leuprorelina (u obliku acetata) |
Pharmaceutical Form | implantat |
Manufacturer | Ebewe Pharma GmbH Nfg. KG, Unterach am Attersee, Austrija Sandoz GmbH, Kundl, Austrija Ever Pharma Jena GmbH, Jena, Njemačka Ever Pharma Jena GmbH, Jena, Njemačka |
Marketing Authorisation Holder | Sandoz d.o.o., Maksimirska 120, Zagreb, Hrvatska |
Marketing Authorisation Date | 13.10.2017 |
MA Period of Validity | unlimited |
Classification Number | UP/I-530-09/16-02/498 |
Registration Number | 381-12-01/30-17-05 |
Prescription | na recept |
Type of prescription | ograničeni recept |
Distribution | u ljekarni |
Advertising to general public | zabranjeno |
ATC Code | L02AE02 |
Medicinal product marketed in the Croatia | Da |
SmPC | download |
PL | download |
Packaging
Direct Healthcare Professional Communication
Name | Date | Download |
---|---|---|
Pismo zdravstvenim radnicima o potrebi strožeg pridržavanja uputa za rekonstituciju i primjenu lijekova koji sadrže depo formulacije leuprorelina kako ne bi došlo do izostanka njihove učinkovitosti | 30.07.2020 | Astellas d.o.o., Sandoz d.o.o., PharmaS d.o.o. |